DMAC vs EXAS · $157.4M cap vs rev $2.76B
DiaMedica Therapeutics Inc (DMAC) versus EXACT Sciences Corporation (EXAS) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
DMAC does not have a complete income-statement cache yet.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
DMAC currently screens at market cap $157.4M. EXAS currently screens at market cap $20.03B.
Not investment advice. Open the DMAC and EXAS stock pages for the full models.
Not investment advice.